Skip to main content
TipRanks
Go Ultimate75% OFF

Republic Healthcare Limited (8357) AI Stock Analysis

1 Followers
HK:8357

Republic Healthcare Limited

(HKEX:8357)

Select Model
Rating:42Neutral
Price Target:HKD 0.13â–¼(-4.41% Downside)
Action:reiterated
Date:11/13/26

Primarily weighed down by weak financial performance with negative margins, cash burn, and eroding equity. Mixed technical signals with oversold conditions provide limited offset, while negative P/E constrains valuation.

Positive Factors
Revenue reboundThe 27.8% TTM revenue rebound indicates renewed top-line momentum after the prior annual period. If sustained, a larger revenue base could improve operating scale and provide management with more capacity to address the company’s current profitability weakness.
Negative Factors
Severe profitability deteriorationNegative gross profit and a net margin near -40% indicate that the current revenue base is not covering the company’s underlying cost structure. Persistent losses reduce reinvestment capacity and make a durable recovery dependent on substantial operating improvement.

Republic Healthcare Limited (8357) vs. iShares MSCI Hong Kong ETF (EWH)

-50%-25%0%25%50%75%100%HK:8357-1.45%EWH+6.50%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
HKD 84.24M
Dividend Yield
―
Average Volume (3M)
1.70M
Price to Earnings (P/E)
-2.7
Beta (1Y)
0.46
Revenue Growth
9.57%
EPS Growth
-179.66%
Country
Hong Kong
Employees
35
Sector
Healthcare
Sector Strength
51
Industry
Medical - Care Facilities

Republic Healthcare Limited Business Overview & Revenue Model

Company Description

Republic Healthcare Limited, a Singaporean primary healthcare enterprise, furnishes an array of medical services, encompassing consultations, diagnostic examinations, and therapeutic interventions. The company delivers diverse treatment solutions for...

Republic Healthcare Limited Financial Statement Overview

Summary

Revenue growth overshadowed by sharply negative gross margins, widening net losses to -40% of sales, deeply negative operating cash flow, and declining equity with rising leverage.

Income Statement

22Negative

Balance Sheet

38Negative

Cash Flow

15Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue10.32M7.84M9.23M10.28M9.04M13.37M
Gross Profit-793.32K-23.92K2.26M2.70M1.89M9.13M
EBITDA-1.43M-1.76M319.04K29.34K-387.88K962.89K
Net Income-4.16M-2.96M-178.16K-855.12K-1.48M-997.93K
Balance Sheet
Total Assets12.87M16.14M14.48M15.64M16.32M19.27M
Cash, Cash Equivalents and Short-Term Investments5.40M6.85M11.52M11.93M11.83M14.27M
Total Debt3.42M5.03M858.22K961.16K810.47K1.55M
Total Liabilities4.90M6.59M1.93M2.89M2.30M3.67M
Stockholders Equity7.96M9.55M12.55M12.75M14.12M15.59M
Cash Flow
Free Cash Flow-3.13M-3.12M51.27K806.24K-1.16M-1.13M
Operating Cash Flow-1.79M-1.90M125.07K899.91K-734.46K-510.07K
Investing Cash Flow-1.71M-2.22M-93.94K831.49K-987.23K-1.56M
Financing Cash Flow-1.17M-813.99K-531.65K-587.62K-689.73K2.28M

Republic Healthcare Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price0.14

Price Trends

50DMA0.16Negative
100DMA0.14Negative
200DMA0.14Negative

Market Momentum

MACD-0.01Positive
RSI32.41Neutral
STOCH12.97Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8357, the sentiment is Negative. The current price of 0.14 is below the 20-day moving average (MA) of 0.19, below the 50-day MA of 0.16, and below the 200-day MA of 0.14, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 32.41 is Neutral, neither overbought nor oversold. The STOCH value of 12.97 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:8357.

Republic Healthcare Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HK:8357 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:3309HK:330976OutperformHKD 1.15B11.045.57%3.23%4.75%―
HK:2135HK:213556NeutralHKD 51.81M3.2912.17%―36.68%―
HK:1846HK:184655NeutralHKD 601.17M244.160.20%2.35%20.54%-96.74%
HK:8307HK:830754NeutralHKD 61.49M65.5519.79%―6.13%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
HK:3886HK:388648NeutralHKD 1.10B77.140.48%1.11%-3.26%―
HK:8357HK:835742NeutralHKD 84.86M-2.73-47.53%―9.57%-179.66%

* Healthcare Sector Average

Performance Comparison

-50%0%50%HK:8357HK:1846HK:2135HK:3309HK:3886HK:8307Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HK:8357 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:8357Republic Healthcare Limited0.14-0.00-1.45%
HK:1846EuroEyes International Eye Clinic Limited1.88-1.29-40.75%
HK:2135Raily Aesthetic Medicine International Holdings Limited0.09-0.04-30.08%
HK:3309C-MER Eye Care Holdings Limited0.93-0.73-43.91%
HK:3886Town Health International Medical Group Ltd.0.16-0.08-34.41%
HK:8307Medicskin Holdings Ltd.0.150.016.90%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026